These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36960789)

  • 41. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems.
    Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M
    Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance and therapeutic potential of prostate cancer antigen-1/ALKBH3 in human renal cell carcinoma.
    Hotta K; Sho M; Fujimoto K; Shimada K; Yamato I; Anai S; Harada H; Tsujikawa K; Konishi N; Shinohara N; Nakajima Y
    Oncol Rep; 2015 Aug; 34(2):648-54. PubMed ID: 26035443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
    Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
    [No Abstract]   [Full Text] [Related]  

  • 44. The metabolomics and lipidomics window into thyroid cancer research.
    Farrokhi Yekta R; Rezaie Tavirani M; Arefi Oskouie A; Mohajeri-Tehrani MR; Soroush AR
    Biomarkers; 2017 Nov; 22(7):595-603. PubMed ID: 27805426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bioinformatic identification of renal cell carcinoma microenvironment-associated biomarkers with therapeutic and prognostic value.
    Zeng Q; Zhang W; Li X; Lai J; Li Z
    Life Sci; 2020 Feb; 243():117273. PubMed ID: 31926244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential Mechanism of
    Ge PY; Qi YY; Qu SY; Zhao X; Ni SJ; Yao ZY; Guo R; Yang NY; Zhang QC; Zhu HX
    Drug Des Devel Ther; 2021; 15():1915-1930. PubMed ID: 33976541
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipidomics in situ: insights into plant lipid metabolism from high resolution spatial maps of metabolites.
    Horn PJ; Chapman KD
    Prog Lipid Res; 2014 Apr; 54():32-52. PubMed ID: 24480404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma.
    Kim J; Thompson B; Han S; Lotan Y; McDonald JG; Ye J
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Dec; 1864(12):158525. PubMed ID: 31513923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of vascular endothelial growth factor in kidney and prostate cancer.
    Delongchamps NB; Peyromaure M
    Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. (1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.
    Cuperlovic-Culf M; Cormier K; Touaibia M; Reyjal J; Robichaud S; Belbraouet M; Turcotte S
    Int J Cancer; 2016 May; 138(10):2439-49. PubMed ID: 26620126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical lipidomics in understanding of lung cancer: Opportunity and challenge.
    Zhang L; Zhu B; Zeng Y; Shen H; Zhang J; Wang X
    Cancer Lett; 2020 Feb; 470():75-83. PubMed ID: 31655086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A cluster of metabolism-related genes predict prognosis and progression of clear cell renal cell carcinoma.
    Liu M; Pan Q; Xiao R; Yu Y; Lu W; Wang L
    Sci Rep; 2020 Jul; 10(1):12949. PubMed ID: 32737333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression.
    Wang R; Li B; Lam SM; Shui G
    J Genet Genomics; 2020 Feb; 47(2):69-83. PubMed ID: 32178981
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipidomics: Prospects from a technological perspective.
    Triebl A; Hartler J; Trötzmüller M; C Köfeler H
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Aug; 1862(8):740-746. PubMed ID: 28341148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro.
    Zieren RC; Dong L; Clark DJ; Kuczler MD; Horie K; Moreno LF; Lih TM; Schnaubelt M; Vermeulen L; Zhang H; de Reijke TM; Pienta KJ; Amend SR
    Med Oncol; 2021 Jul; 38(9):105. PubMed ID: 34331598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
    Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
    Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers.
    Skotland T; Ekroos K; Kauhanen D; Simolin H; Seierstad T; Berge V; Sandvig K; Llorente A
    Eur J Cancer; 2017 Jan; 70():122-132. PubMed ID: 27914242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.
    Osunkoya AO; Yin-Goen Q; Phan JH; Moffitt RA; Stokes TH; Wang MD; Young AN
    Hum Pathol; 2009 Dec; 40(12):1671-8. PubMed ID: 19695674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ectopic expression of the TERE1 (UBIAD1) protein inhibits growth of renal clear cell carcinoma cells: altered metabolic phenotype associated with reactive oxygen species, nitric oxide and SXR target genes involved in cholesterol and lipid metabolism.
    Fredericks WJ; Yin H; Lal P; Puthiyaveettil R; Malkowicz SB; Fredericks NJ; Tomaszewski J; Rauscher FJ; Malkowicz SB
    Int J Oncol; 2013 Aug; 43(2):638-52. PubMed ID: 23759948
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.